Gilead Sciences

Gilead Sciences OCF Margin

The Operating Cash Flow Margin of Gilead Sciences (GILD) as of Nov 19, 2026 is 34.03 %. In the previous year, Operating Cash Flow Margin was 37.66 % — a change of -9.63% (lower).

OCF Margin

34.03 %

YoY

-9.63%

Last updated:

Operating Cash Flow Margin of Gilead Sciences is 2025 34.03 % . Operating Cash Flow Margin of Gilead Sciences was 2024 37.66 % . It decreases by -9.63% lower compared to the previous year.

The Gilead Sciences OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2018
37.96 USD
Jan 1, 2019
40.73 USD
Jan 1, 2020
33.08 USD
Jan 1, 2021
41.69 USD
Jan 1, 2022
33.25 USD
Jan 1, 2023
29.53 USD
Jan 1, 2024
37.66 USD
Jan 1, 2025
34.03 USD
The Gilead Sciences OCF Margin history
YEAROCF MarginYoY
34.03 %-9.63%
37.66 %+27.54%
29.53 %-11.21%
33.25 %-20.24%
41.69 %+26.02%
33.08 %-18.78%
40.73 %+7.30%
37.96 %-16.70%
45.57 %-18.75%
56.09 %-13.84%
65.11 %+26.42%
51.50 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Gilead Sciences Stock analysis

What does Gilead Sciences do? Gilead Sciences Inc, also known as Gilead, is an American biopharmaceutical company specializing in the development and production of drugs. It was founded in 1987 by Michael Riordan and has since become one of the largest biopharmaceutical companies in the world. Gilead focuses on developing drugs for difficult-to-treat diseases such as HIV, hepatitis, cancer, and inflammatory diseases. Its business model is divided into three segments: HIV, liver diseases, and oncology. The company has made significant advancements in antiviral therapies and aims to improve patients' lives and cure diseases through the development of new medical products and therapies. In the HIV segment, Gilead offers drugs such as Truvada, Atripla, and Biktarvy. In liver diseases, the company has focused on fighting hepatitis C and offers drugs like Harvoni, Sovaldi, and Epclusa. In the field of oncology, Gilead develops drugs for cancer treatment, particularly targeting specific mutations. The company has made notable progress in this area, such as developing the first approved CAR-T-cell therapy for lymphoma treatment, Yescarta. Gilead has also gained attention through its innovative research and development work, including licensing the CRISPR-Cas9 technology for targeted gene editing. Overall, Gilead Sciences Inc has had a remarkable success story and is considered one of the most significant biopharmaceutical companies globally, setting standards and bringing hope for cure to many people with serious illnesses. Gilead Sciences is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Gilead Sciences stock

Operating Cash Flow Margin of Gilead Sciences is 34.03 % in 2025.

Operating Cash Flow Margin of Gilead Sciences changed from 37.66 % to 34.03 %, representing a -9.63% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin Gilead Sciences since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's Gilead Sciences with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Gilead Sciences

All Key Metrics — Gilead Sciences